Dissecting Spesolimab's Approval With Boehringer Ingelheim's Carine Boustany
Business Of Biotech
00:00
The Inflection Points in Bio-Pharma Development
A good portion of our audience are new and emerging bio-pharma leaders who perhaps they've seen some commercial success and approval success in previous careers with bigger companies. Many of them have yet to understand or experience this kind of success. So I guess walk us through some of the inflection points, right? You mentioned a couple of those clinical readouts. Walk us through sort of what those major inflection points are on a journey like this.
Transcript
Play full episode
